References
Key articles
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].Full text
Scottish Intercollegiate Guidelines Network. Management of schizophrenia: a national clinical guideline. March 2013 [internet publication].Full text
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2023.
American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, third edition. 2021 [internet publication].Full text
Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Full text Abstract
Reference articles
1. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. March 2014 [internet publication].Full text
2. Scottish Intercollegiate Guidelines Network. Management of schizophrenia: a national clinical guideline. March 2013 [internet publication].Full text
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2023.
4. World Health Organization. International statistical classification of diseases and related health problems (ICD): ICD-11. Sep 2022 [internet publication].Full text
5. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: the NICE guideline on treatment and management. 2014 [internet publication].Full text
6. McGrath J, Saha S, Chant D, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.Full text Abstract
7. McGrath JJ. Myths and plain truths about schizophrenia epidemiology - the NAPE lecture 2004. Acta Psychiatr Scand. 2005 Jan;111(1):4-11. Abstract
8. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl. 1992;20:1-97. Abstract
9. American Psychiatric Association. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia, third edition. 2021 [internet publication].Full text
10. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022 Feb;9(2):137-50.Full text Abstract
11. Piotrowski P, Gondek TM, Królicka-Deręgowska A, et al. Causes of mortality in schizophrenia: an updated review of European studies. Psychiatr Danub. 2017 Jun;29(2):108-20. Abstract
12. Mitchell AJ, Malone D. Physical health and schizophrenia. Curr Opin Psychiatry. 2006 Jul;19(4):432-7. Abstract
13. Fazel S, Wolf A, Palm C, et al. Violent crime, suicide, and premature mortality in patients with schizophrenia and related disorders: a 38-year total population study in Sweden. Lancet Psychiatry. 2014 Jun;1(1):44-54.Full text Abstract
14. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712. Abstract
15. Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS One. 2012;7(3):e31660.Full text Abstract
16. Häfner H, Maurer K, Löffler W, et al. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993 Jan;162:80-6. Abstract
17. McGrath JJ, Welham JL. Season of birth and schizophrenia: a systematic review and meta-analysis of data from the Southern Hemisphere. Schizophr Res. 1999 Feb 15;35(3):237-42. Abstract
18. Werbeloff N, Levine SZ, Rabinowitz J. Elaboration on the association between immigration and schizophrenia: a population-based national study disaggregating annual trends, country of origin and sex over 15 years. Soc Psychiatry Psychiatr Epidemiol. 2012 Feb;47(2):303-11. Abstract
19. Bourque F, van der Ven E, Malla A. A meta-analysis of the risk for psychotic disorders among first- and second-generation immigrants. Psychol Med. 2011 May;41(5):897-910. Abstract
20. National Institute for Health and Care Excellence. Psychosis and schizophrenia in children and young people: recognition and management. October 2016 [internet publication].Full text
21. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997 Oct;104(4):667-85. Abstract
22. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry. 2000 Feb 1;47(3):210-20. Abstract
23. McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia: an overview. JAMA Psychiatry. 2020 Feb 1;77(2):201-10. Abstract
24. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003 Dec;60(12):1187-92.Full text Abstract
25. Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019 Oct 31;381(18):1753-61. Abstract
26. Bennett MR. Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Prog Neurobiol. 2011 Nov;95(3):275-300. Abstract
27. Kuswanto CN, Teh I, Lee T-S, et al. Diffusion tensor imaging findings of white matter changes in first episode schizophrenia: a systematic review. Clin Psychopharmacol Neurosci. 2012 Apr;10(1):13-24.Full text Abstract
28. ENIGMA Clinical High Risk for Psychosis Working Group; Jalbrzikowski M, Hayes RA, Wood SJ, et al. Association of structural magnetic resonance imaging measures with psychosis onset in individuals at clinical high risk for developing psychosis: an ENIGMA working group mega-analysis. JAMA Psychiatry. 2021 Jul 1;78(7):753-66.Full text Abstract
29. McCarley RW, Wible CG, Frumin M, et al. MRI anatomy of schizophrenia. Biol Psychiatry. 1999 May 1;45(9):1099-119.Full text Abstract
30. Kambeitz J, Kambeitz-Ilankovic L, Cabral C, et al. Aberrant functional whole-brain network architecture in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2016 Jul;42 Suppl 1(suppl 1):S13-21.Full text Abstract
31. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015 Jan 15;77(2):147-57.Full text Abstract
32. Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. Abstract
33. Laruelle M. Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q J Nucl Med. 1998 Sep;42(3):211-21. Abstract
34. Laruelle M, Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999 Dec;13(4):358-71. Abstract
35. Howes OD, Bukala BR, Beck K. Schizophrenia: from neurochemistry to circuits, symptoms and treatments. Nat Rev Neurol. 2024 Jan;20(1):22-35. Abstract
36. Parellada E, Gassó P. Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia. Transl Psychiatry. 2021 May 6;11(1):271.Full text Abstract
37. Smith TE, Hull JW, Huppert JD, et al. Insight and recovery from psychosis in chronic schizophrenia and schizoaffective disorder patients. J Psychiatr Res. 2004 Mar-Apr;38(2):169-76. Abstract
38. Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007 Jun 15;75(12):1821-9.Full text Abstract
39. Miller B, Messias E, Miettunen J, et al. Meta-analysis of paternal age and schizophrenia risk in male versus female offspring. Schizophr Bull. 2011 Sep;37(5):1039-47.Full text Abstract
40. Clarke MC, Harley M, Cannon M. The role of obstetric events in schizophrenia. Schizophr Bull. 2006 Jan;32(1):3-8.Full text Abstract
41. Macleod J, Davey Smith G, Hickman M. Does cannabis use cause schizophrenia? Lancet. 2006 Apr 1;367(9516):1055. Abstract
42. Arseneault L, Cannon M, Witton J, et al. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004 Feb;184:110-7. Abstract
43. Arendt M, Rosenberg R, Foldager L, et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005 Dec;187:510-5. Abstract
44. Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011 Mar 1;342:d738.Full text Abstract
45. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010 May;67(5):440-7.Full text Abstract
46. Hjorthøj C, Albert N, Nordentoft M. Association of substance use disorders with conversion from schizotypal disorder to schizophrenia. JAMA Psychiatry. 2018 Jul 1;75(7):733-9.Full text Abstract
47. Hindley G, Beck K, Borgan F, et al. Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry. 2020 Apr;7(4):344-53.Full text Abstract
48. Belbasis L, Köhler CA, Stefanis N, et al. Risk factors and peripheral biomarkers for schizophrenia spectrum disorders: an umbrella review of meta-analyses. Acta Psychiatr Scand. 2018 Feb;137(2):88-97. Abstract
49. Schoeler T, Petros N, Di Forti M, et al. Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: a prospective analysis. Lancet Psychiatry. 2017 Aug;4(8):627-33.Full text Abstract
50. Ziermans T, de Wit S, Schothorst P, et al. Neurocognitive and clinical predictors of long-term outcome in adolescents at ultra-high risk for psychosis: a 6-year follow-up. PLoS One. 2014 Apr 4;9(4):e93994.Full text Abstract
51. Dazzan P, Murray RM. Neurological soft signs in first-episode psychosis: a systematic review. Br J Psychiatry Suppl. 2002 Sep;43:s50-7.Full text Abstract
52. Tosato S, Dazzan P. The psychopathology of schizophrenia and the presence of neurological soft signs: a review. Curr Opin Psychiatry. 2005 May;18(3):285-8. Abstract
53. Mittal VA, Dean DJ, Bernard JA, et al. Neurological soft signs predict abnormal cerebellar-thalamic tract development and negative symptoms in adolescents at high risk for psychosis: a longitudinal perspective. Schizophr Bull. 2014 Nov;40(6):1204-15.Full text Abstract
54. Dean DJ, Bernard JA, Orr JM, et al. Cerebellar morphology and procedural learning impairment in neuroleptic-naive youth at ultrahigh risk of psychosis. Clin Psychol Sci. 2014 Mar;2(2):152-64.Full text Abstract
55. Bernard JA, Dean DJ, Kent JS, et al. Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity. Hum Brain Mapp. 2014 Aug;35(8):4064-78.Full text Abstract
56. Corcoran C, Walker E, Huot R, et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull. 2003;29(4):671-92. Abstract
57. Morgan C, Fisher H. Environment and schizophrenia: environmental factors in schizophrenia: childhood trauma - a critical review. Schizophr Bull. 2007 Jan;33(1):3-10.Full text Abstract
58. Stafford MR, Jackson H, Mayo-Wilson E, et al. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ. 2013 Jan 18;346:f185.Full text Abstract
59. Fusar-Poli P, Salazar de Pablo G, Correll CU, et al. Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiatry. 2020 Jul 1;77(7):755-65. Abstract
60. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. May 2015 [internet publication].Full text
61. Royal College of Psychiatrists. Psychiatry attachments [internet publication].Full text
62. Cole-King A, Platt S. Suicide prevention for physicians: identification, intervention and mitigation of risk. Medicine. 2017 Jan 27;45(3):131-4.
63. National Institute for Health and Care Excellence. Decision-making and mental capacity. October 2018 [internet publication].Full text
64. Department for Constitutional Affairs. Mental Capacity Act 2005: Code of Practice. 2007 [internet publication].Full text
65. National Institute for Health and Care Excellence. Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. June 2021 [internet publication].Full text
66. Soltan M, Girguis J. How to approach the mental state examination. BMJ. 2017 May 8;357:j1821. Abstract
67. Griswold KS, Del Regno PA, Berger RC. Recognition and differential diagnosis of psychosis in primary care. Am Fam Physician. 2015 Jun 15;91(12):856-63.Full text Abstract
68. Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020 Jan;34(1):3-78.Full text Abstract
69. The National Archives. Mental Health Act 2007 [internet publication].Full text
70. The National Archives. Mental Health (Scotland) Act 2015 [internet publication].Full text
71. The National Archives. Mental Capacity Act (Northern Ireland) 2016 [internet publication].Full text
72. Puntis S, Minichino A, De Crescenzo F, et al. Specialised early intervention teams for recent-onset psychosis. Cochrane Database Syst Rev. 2020 Nov 2;(11):CD013288.Full text Abstract
73. Lee R, Leighton SP, Thomas L, et al. Prediction models in first-episode psychosis: systematic review and critical appraisal. Br J Psychiatry. 2022 Jan 24;220:1-13.Full text Abstract
74. Soldatos RF, Cearns M, Nielsen MØ, et al. Prediction of early symptom remission in two independent samples of first-episode psychosis patients using machine learning. Schizophr Bull. 2022 Jan 21;48(1):122-33.Full text Abstract
75. Trovão N, Prata J, VonDoellinger O, et al. Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia. Psychiatry Investig. 2019 Mar;16(3):177-84.Full text Abstract
76. Wang B, Zartaloudi E, Linden JF, et al. Neurophysiology in psychosis: the quest for disease biomarkers. Transl Psychiatry. 2022 Mar 11;12(1):100.Full text Abstract
77. Soares-Weiser K, Maayan N, Bergman H, et al. First rank symptoms for schizophrenia. Cochrane Database Syst Rev. 2015 Jan 25;(1):CD010653.Full text Abstract
78. Lewandowski KE, DePaola J, Camsari GB, et al. Tactile, olfactory, and gustatory hallucinations in psychotic disorders: a descriptive study. Ann Acad Med Singap. 2009 May;38(5):383-5.Full text Abstract
79. Sass L, Parnas, J. Thought disorder, subjectivity, and the self. Schizophr Bull. 2017 May 1;43(3):497-502.Full text
80. Carpenter WT Jr, Strauss JS, Muleh S. Are there pathognomonic symptoms in schizophrenia? An empiric investigation of Schneider's first-rank symptoms. Arch Gen Psychiatry. 1973 Jun;28(6):847-52. Abstract
81. Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017 Mar 1;43(2):240-4.Full text Abstract
82. Grillo L. A possible link between anxiety and schizophrenia and a possible role of anhedonia. Schizophr Res Treatment. 2018 Jan 17;2018:5917475.Full text Abstract
83. Dondé C, Vignaud P, Poulet E, et al. Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines. Acta Psychiatr Scand. 2018 Oct;138(4):289-99. Abstract
84. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020 Sep 1;177(9):868-72.Full text Abstract
85. Cole-King A, Green G, Gask L, et al. Suicide mitigation: a compassionate approach to suicide prevention. Adv Psychiatr Treat. 2013;19(4):276-83.Full text
86. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010 Nov;24(4 suppl):81-90.Full text Abstract
87. Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication].Full text
88. Nordentoft M, Madsen T, Fedyszyn I. Suicidal behavior and mortality in first-episode psychosis. J Nerv Ment Dis. 2015 May;203(5):387-92. Abstract
89. Ventriglio A, Gentile A, Bonfitto I, et al. Suicide in the early stage of schizophrenia. Front Psychiatry. 2016 Jun 27;7:116.Full text Abstract
90. Morrison P, Taylor DM, McGuire P. The Maudsley guidelines on advanced prescribing in psychosis. Chichester: Wiley-Blackwell; 2019.
91. Beattie N, Shannon C, Kavanagh M, et al. Predictors of PTSD symptoms in response to psychosis and psychiatric admission. J Nerv Ment Dis. 2009 Jan;197(1):56-60. Abstract
92. Mortensen PB, Pedersen MG, Pedersen CB. Psychiatric family history and schizophrenia risk in Denmark: which mental disorders are relevant? Psychol Med. 2010 Feb;40(2):201-10. Abstract
93. Eaton WW, Mortensen PB, Frydenberg M. Obstetric factors, urbanization and psychosis. Schizophr Res. 2000 Jun 16;43(2-3):117-23. Abstract
94. Hollander AC, Dal H, Lewis G, et al. Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden. BMJ. 2016 Mar 15;352:i1030.Full text Abstract
95. Dalman C, Allebeck P, Cullberg J, et al. Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry. 1999 Mar;56(3):234-40.Full text Abstract
96. Sørensen HJ, Mortensen EL, Schiffman J, et al. Early developmental milestones and risk of schizophrenia: a 45-year follow-up of the Copenhagen Perinatal Cohort. Schizophr Res. 2010 May;118(1-3):41-7.Full text Abstract
97. Amminger GP, Pape S, Rock D, et al. Relationship between childhood behavioral disturbance and later schizophrenia in the New York high-risk project. Am J Psychiatry. 1999 Apr;156(4):525-30.Full text Abstract
98. Morgese MG, Trabace L. Maternal malnutrition in the etiopathogenesis of psychiatric diseases: role of polyunsaturated fatty acids. Brain Sci. 2016 Jul 27;6(3):24.Full text Abstract
99. Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011 Mar;37(2):284-90.Full text Abstract
100. Adorjan K, Papiol S, Gade K, et al. Polygenic risk burden and cannabis use comorbidity in patients with schizophrenia and bipolar disorder. Euro Neuropsych. 2019;29 (Suppl 3):S951.
101. Thoma P, Daum I. Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings. Psychiatry Clin Neurosci. 2013 Sep;67(6):367-83. Abstract
102. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997 Mar-Apr;14(2):103-11. Abstract
103. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010 Jun;133 (Pt 6):1655-67.Full text Abstract
104. Wang M, Cao X, Liu Q, et al. Clinical features of limbic encephalitis with LGI1 antibody. Neuropsychiatr Dis Treat. 2017 Jun 16;13:1589-96.Full text Abstract
105. Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018 Feb 1;141(2):348-56.Full text Abstract
106. Taylor DM, Gaughran F, Pillinger T. The Maudsley practice guidelines for physical health conditions in psychiatry. Chichester: Wiley-Blackwell; 2020.
107. Royal College of Emergency Medicine. The patient who absconds. June 2020 [internet publication].Full text
108. Betz ME, Boudreaux ED. Managing suicidal patients in the emergency department. Ann Emerg Med. 2016 Feb;67(2):276-82.Full text Abstract
109. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits - a reconsideration. J Psychopharmacol. 2013 Nov;27(11):967-71. Abstract
110. Cookson J. Rapid tranquillisation: the science and advice. BJPsych Advances. 2018 Sep;24(5):346-58.Full text
111. Royal College of Psychiatrists. The risks and benefits of high-dose antipsychotic medication. November 2014 (revised January 2023) [internet publication].Full text
112. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016 Aug;30(8):717-48.Full text Abstract
113. Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017 Mar 1;174(3):216-29.Full text Abstract
114. Masuda T, Misawa F, Takase M, et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. JAMA Psychiatry. 2019 Oct 1;76(10):1052-62.Full text Abstract
115. Chan JKN, Wong CSM, Or PCF, et al. Risk of mortality and complications in patients with schizophrenia and diabetes mellitus: population-based cohort study. Br J Psychiatry. 2021 Jul;219(1):375-82.Full text Abstract
116. Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301. Abstract
117. Jones C, Hacker D, Meaden A, et al. Cognitive behavioural therapy plus standard care versus standard care plus other psychosocial treatments for people with schizophrenia. Cochrane Database Syst Rev. 2018 Nov 15;11(11):CD008712.Full text Abstract
118. Jones C, Hacker D, Xia J, et al. Cognitive behavioural therapy plus standard care versus standard care for people with schizophrenia. Cochrane Database Syst Rev. 2018 Dec 20;(12):CD007964.Full text Abstract
119. Paton C. Benzodiazepines and disinhibition: a review. Psychiatric Bulletin. 2002 Dec;26(12):460-2.Full text
120. British National Formulary 77. Clozapine. London: BMJ Group, RCPCH Publications Ltd and the Royal Pharmaceutical Society of Great Britain. 2020.Full text
121. Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry. 2020 Jan;7(1):93-108. Abstract
122. Hynes C, Keating D, McWilliams S, et al. Glasgow antipsychotic side-effects scale for clozapine: development and validation of a clozapine-specific side-effects scale. Schizophr Res. 2015 Oct;168(1-2):505-13. Abstract
123. Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449-68.Full text Abstract
124. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37. Abstract
125. Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016.Full text Abstract
126. Walter F, Carr MJ, Mok PLH, et al. Multiple adverse outcomes following first discharge from inpatient psychiatric care: a national cohort study. Lancet Psychiatry. 2019 Jul;6(7):582-9.Full text Abstract
127. Reynolds RJ, Day SM, Shafer A, et al. Mortality rates and excess death rates for the seriously mentally ill. J Insur Med. 2018;47(4):212-9.Full text Abstract
128. Tam J, Warner KE, Meza R. Smoking and the reduced life expectancy of individuals with serious mental illness. Am J Prev Med. 2016 Dec;51(6):958-66. Abstract
129. Gilbody S, Peckham E, Bailey D, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. Lancet Psychiatry. 2019 May;6(5):379-90.Full text Abstract
130. Hobkirk AL, Towe SL, Lion R, et al. Primary and secondary HIV prevention among persons with severe mental illness: recent findings. Curr HIV/AIDS Rep. 2015 Dec;12(4):406-12.Full text Abstract
131. Hughes E, Bassi S, Gilbody S, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry. 2016 Jan;3(1):40-8.Full text Abstract
132. Bauer-Staeb C, Jörgensen L, Lewis G, et al. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017 Sep;4(9):685-93.Full text Abstract
133. Lean M, Fornells-Ambrojo M, Milton A, et al. Self-management interventions for people with severe mental illness: systematic review and meta-analysis. Br J Psychiatry. 2019 May;214(5):260-8.Full text Abstract
134. Semple D, Smyth R. Oxford handbook of psychiatry. 3rd ed. Oxford: Oxford University Press; 2013.
135. Alphs L, Nasrallah HA, Bossie CA, et al. Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. Int Clin Psychopharmacol. 2016 Jul;31(4):202-9.Full text Abstract
136. Colizzi M, Carra E, Fraietta S, et al. Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res. 2016 Feb;170(2-3):311-7. Abstract
137. Tsuda Y, Saruwatari J, Yasui-Furukori N. Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open. 2014 Mar 4;4(3):e004216.Full text Abstract
138. Medicines and Healthcare products Regulatory Agency. Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus. October 2017 [internet publication].Full text
139. National Institute for Health and Care Excellence. Guidance on the use of electroconvulsive therapy. October 2009 [internet publication].Full text
140. Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000076.Full text Abstract
141. Chanpattana W, Chakrabhand ML, Sackeim HA, et al. Continuation ECT in treatment-resistant schizophrenia: a controlled study. J ECT. 1999 Sep;15(3):178-92. Abstract
142. Sinclair DJ, Zhao S, Qi F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev. 2019 Mar 19;(3):CD011847.Full text Abstract
143. Balu DT, Coyle JT. The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond. Curr Opin Pharmacol. 2015 Feb;20:109-15.Full text Abstract
144. Fleischhacker WW, Podhorna J, Gröschl M, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. Abstract
145. Foster DJ, Bryant ZK, Conn PJ. Targeting muscarinic receptors to treat schizophrenia. Behav Brain Res. 2021 May 7;405:113201.Full text Abstract
146. Paul SM, Yohn SE, Popiolek M, et al. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022 Sep;179(9):611-27.Full text Abstract
147. Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021 Feb 25;384(8):717-26.Full text Abstract
148. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024 Jan 13;403(10422):160-70. Abstract
149. Tsapakis EM, Diakaki K, Miliaras A, et al. Novel compounds in the treatment of schizophrenia: a selective review. Brain Sci. 2023 Aug 11;13(8):1193.Full text Abstract
150. Krystal JH, Kane JM, Correll CU, et al. Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2022 Dec 17;400(10369):2210-20. Abstract
151. Kulkarni J, Gavrilidis E, Gwini SM, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women: a randomized clinical trial. JAMA Psychiatry. 2016 Sep 1;73(9):947-54. Abstract
152. Weiser M, Levi L, Zamora D, et al. Effect of adjunctive estradiol on schizophrenia among women of childbearing age: a randomized clinical trial. JAMA Psychiatry. 2019 Oct 1;76(10):1009-17.Full text Abstract
153. Nair PC, Chalker JM, McKinnon RA, et al. Trace amine-associated receptor 1 (TAAR1): molecular and clinical insights for the treatment of schizophrenia and related comorbidities. ACS Pharmacol Transl Sci. 2022 Mar 11;5(3):183-8.Full text Abstract
154. Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020 Apr 16;382(16):1497-506.Full text Abstract
155. Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021 Dec 9;7(1):63.Full text Abstract
156. Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sci. 2021 Dec 7;22(24):13185.Full text Abstract
157. Correll CU, Newcomer JW, Silverman B, et al. Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. Am J Psychiatry. 2020 Dec 1;177(12):1168-78.Full text Abstract
158. Greenwood J, Acharya RB, Marcellus V, et al. Lumateperone: a novel antipsychotic for schizophrenia. Ann Pharmacother. 2021 Jan;55(1):98-104.Full text Abstract
159. Correll CU, Davis RE, Weingart M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020 Apr 1;77(4):349-58.Full text Abstract
160. Lieberman JA, Davis RE, Correll CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry. 2016 Jun 15;79(12):952-61.Full text Abstract
161. Correll CU, Vanover KE, Davis RE, et al. Safety and tolerability of lumateperone 42 mg: an open-label antipsychotic switch study in outpatients with stable schizophrenia. Schizophr Res. 2021 Feb;228:198-205.Full text Abstract
162. Pollack CV Jr. Inhaled loxapine for the urgent treatment of acute agitation associated with schizophrenia or bipolar disorder. Curr Med Res Opin. 2016 Jul;32(7):1253-60. Abstract
163. Penttilä M, Jääskeläinen E, Hirvonen N, et al. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2014 Aug;205(2):88-94.Full text Abstract
164. Cechnicki A, Cichocki Ł, Kalisz A, et al. Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Res. 2014 Nov 30;219(3):420-5. Abstract
165. Huxley P, Krayer A, Poole R, et al. Schizophrenia outcomes in the 21st century: a systematic review. Brain Behav. 2021 Jun;11(6):e02172.Full text Abstract
166. Kern RS, Glynn SM, Horan WP, et al. Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull. 2009 Mar;35(2):347-61.Full text Abstract
167. Horan WP, Kern RS, Shokat-Fadai K, et al. Social cognitive skills training in schizophrenia: an initial efficacy study of stabilized outpatients. Schizophr Res. 2009 Jan;107(1):47-54.Full text Abstract
168. Isaacs AN, Brooks H, Lawn S, et al. Effectiveness of personal recovery facilitators in adults with schizophrenia and other psychoses: a systematic review of reviews and narrative synthesis. Schizophr Res. 2022 Aug;246:132-47. Abstract
169. National Institute for Health and Care Excellence. Rehabilitation for adults with complex psychosis. August 2020 [internet publication].Full text
170. Carmona VR, Gómez-Benito J, Huedo-Medina TB, et al. Employment outcomes for people with schizophrenia spectrum disorder: a meta-analysis of randomized controlled trials. Int J Occup Med Environ Health. 2017 May 8;30(3):345-66.Full text Abstract
171. Kane JM, McGlashan TH. Treatment of schizophrenia. Lancet. 1995 Sep 23;346(8978):820-5. Abstract
172. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-51. Abstract
173. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996;22(2):241-56. Abstract
174. Malla AK, Norman RM, Manchanda R, et al. Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment. Psychiatr Serv. 2002 Apr;53(4):458-63. Abstract
175. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001 Apr;31(3):381-400. Abstract
176. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry. 1999 Oct 1;46(7):899-907. Abstract
177. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter? Psychol Med. 2003 Jan;33(1):97-110. Abstract
178. Craig TJ, Bromet EJ, Fennig S, et al. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry. 2000 Jan;157(1):60-6. Abstract
179. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999 Mar;56(3):241-7. Abstract
180. Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718.Full text Abstract
181. Correll CU, Galling B, Pawar A, et al. Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-65.Full text Abstract
182. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999 Apr;156(4):544-9. Abstract
183. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66 suppl 6:5-10. Abstract
184. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011 Aug;25(8):659-71. Abstract
185. Gray R, Gournay K. What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs. 2000 Jun;7(3):205-11. Abstract
186. Velamoor VR, Swamy GN, Parmar RS, et al. Management of suspected neuroleptic malignant syndrome. Can J Psychiatry. 1995 Nov;40(9):545-50. Abstract
187. Klemp M, Tvete IF, Skomedal T, et al. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011 Dec;31(6):698-704. Abstract
188. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry. 2005 Jul;187:9-20. Abstract
189. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.Full text Abstract
190. Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006 Dec;10(3-4):221-33. Abstract
191. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253.Full text Abstract
192. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988 Nov;39(11):1172-7. Abstract
193. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol. 2001 Sep;58(9):1379-82.Full text Abstract
194. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62 Suppl 7:22-31.Full text Abstract
195. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003 Jan;28 suppl 1:83-96. Abstract
196. Das C, Mendez G, Jagasia S, et al. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012 Aug;24(3):225-39. Abstract
197. Mahmood S, Booker I, Huang J, et al. Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents. J Clin Psychopharmacol. 2013 Feb;33(1):90-4. Abstract
198. Zhang Y, Dai G. Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China. Hum Psychopharmacol. 2012 Nov;27(6):605-14. Abstract
199. Mukundan A, Faulkner G, Cohn T, et al. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629.Full text Abstract
200. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res. 2004 Dec 1;71(2-3):195-212. Abstract
201. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68 (Suppl 1):20-7. Abstract
202. Halbreich U, Kahn LS. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract. 2003 Sep;9(5):344-53. Abstract
203. Labad J, Montalvo I, González-Rodríguez A, et al. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis. Schizophr Res. 2020 Aug;222:88-96. Abstract
204. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012;38(3):281-301. Abstract
205. Bacconi L, Gressier F. Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: a literature review [in French]. Encephale. 2017 Feb;43(1):55-61. Abstract
206. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001 Nov;158(11):1774-82.Full text Abstract
207. Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract. 2014 May;20(3):196-206. Abstract
208. Myles N, Myles H, Xia S, et al. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018 Aug;138(2):101-9. Abstract
209. Kar N, Barreto S, Chandavarkar R. Clozapine monitoring in clinical practice: beyond the mandatory requirement. Clin Psychopharmacol Neurosci. 2016 Nov 30;14(4):323-9.Full text Abstract
210. Legge SE, Dennison CA, Pardiñas AF, et al. Clinical indicators of treatment-resistant psychosis. Br J Psychiatry. 2020 May;216(5):259-66.Full text Abstract
211. Vermeulen J, van Rooijen G, Doedens P, et al. Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis. Psychol Med. 2017 Oct;47(13):2217-28. Abstract
212. Katschnig H. Rehabilitation in schizophrenia - guidelines for including psychosocial measures [in German]. Wien Med Wochenschr. 1998;148(11-12):273-80. Abstract
213. Farooq S, Johal RK, Ziff C, et al. Different communication strategies for disclosing a diagnosis of schizophrenia and related disorders. Cochrane Database Syst Rev. 2017 Oct 24;(10):CD011707.Full text Abstract
214. Moncrieff J, Crellin N, Stansfeld J, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial. Lancet Psychiatry. 2023 Nov;10(11):848-59.Full text Abstract
215. Stubbs B, Vancampfort D, Hallgren M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018 Oct;54:124-44. Abstract
Comorbidities Manager reference articles
216. Patel MX, Sethi FN, Barnes TR, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: de-escalation and rapid tranquillisation. J Psychopharmacol. 2018 Jun;32(6):601-40 Abstract
217. Díaz-Gutiérrez MJ, Martínez-Cengotitabengoa M, Sáez de Adana E, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017 Jul;101:17-22 Abstract
218. Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia. CMAJ. 2017 Apr 10;189(14):E517-8Full text Abstract
219. Wijeyakuhan N, Gruber R, Rattray NA. The cascade of benzodiazepine prescribing for hospitalized geriatric patients. J Community Hosp Intern Med Perspect. 2020 Oct 29;10(6):542-5Full text Abstract
220. Baldwin DS, Aitchison K, Bateson A, et al. Benzodiazepines: risks and benefits: a reconsideration. J Psychopharmacol. 2013 Nov;27(11):967-71 Abstract
221. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 14th edition. Chichester: Wiley-Blackwell; 2021
222. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J. 2014 Aug;44(2):332-40Full text Abstract
223. Medicines and Healthcare products Regulatory Agency. Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression. March 2020 [internet publication]Full text
224. Medicines and Healthcare products Regulatory Agency. Haloperidol (haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. Dec 2021 [internet publication]Full text
225. British Geriatrics Society. CGA in primary care settings: patients presenting with confusion and delirium. Jan 2019 [internet publication]Full text
226. National Institute for Health and Care Excellence. Violence and aggression: short-term management in mental health, health and community settings. May 2015 [internet publication]Full text
227. Wang MT, Tsai CL, Lin CW, et al. Association between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry. 2017 Mar 1;74(3):252-60Full text Abstract
228. Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017 Feb;39(1):16-25 Abstract
229. Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016 Apr;22(2):435-63.Full text Abstract
230. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs. 2011 Aug;25(8):659-71 Abstract
231. National Institute for Health and Care Excellence. Violent and aggressive behaviours in people with mental health problems: quality statement 4 – physical health after rapid tranquillisation. June 2017 [internet publication]Full text
232. Public Health England. NHS RightCare toolkit: physical ill-health and CVD prevention in people with severe mental Illness. March 2019 [internet publication]Full text
233. Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017 Apr;4(4):295-301 Abstract
234. Cooper SJ, Reynolds GP, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016 Aug;30(8):717-48Full text Abstract
235. Firth J, Siddiqi N, Koyanagi A, et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry. 2019 Aug;6(8):675-712 Abstract
236. World Health Organization. Schizophrenia. January 2022 [internet publication]Full text
237. Joint British Diabetes Societies for Inpatient Care. The management of diabetes in adults and children with psychiatric disorders in inpatient settings. May 2017 [internet publication]Full text
238. Pendlebury ST, Klaus SP, Mather M, et al. Routine cognitive screening in older patients admitted to acute medicine: abbreviated mental test score (AMTS) and subjective memory complaint versus Montreal Cognitive Assessment and IQCODE. Age Ageing. 2015 Oct 13;44(6):1000-5Full text Abstract
239. Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing. 1972 Nov;1(4):233-8 Abstract
240. Emery A, Wells J, Klaus SP, et al. Underestimation of cognitive impairment in older inpatients by the Abbreviated Mental Test Score versus the Montreal Cognitive Assessment: cross-sectional observational study. Dement Geriatr Cogn Dis Extra. 2020 Sep-Dec;10(3):205-15.Full text Abstract
241. Scottish Intercollegiate Guidelines Network. Risk reduction and management of delirium. Mar 2019 [internet publication].Full text
242. Bellelli G, Morandi A, Davis DH, et al. Validation of the 4AT, a new instrument for rapid delirium screening: a study in 234 hospitalised older people. Age Ageing. 2014 Mar 2;43(4):496-502.Full text Abstract
243. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. Jan 2023 [internet publication].Full text
244. Tieges Z, Maclullich AMJ, Anand A, et al. Diagnostic accuracy of the 4AT for delirium detection in older adults: systematic review and meta-analysis. Age Ageing. 2021 May 5;50(3):733-43.Full text Abstract
245. Zhang XM, Jiao J, Xie XH, et al. The association between frailty and delirium among hospitalized patients: an updated meta-analysis. J Am Med Dir Assoc. 2021 Mar;22(3):527-34. Abstract
246. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Full text
247. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Nov 9;6(12):681-94 Abstract
248. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020 Oct;51(10):3156-68.Full text Abstract
249. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13 Abstract
250. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 May 4;47(6):e98-e169Full text Abstract
251. Hogervorst VM, Buurman BM, De Jonghe A, et al. Emergency department management of older people living with frailty: a guide for emergency practitioners. Emerg Med J. 2021 Sep;38(9):724-9 Abstract
252. British Geriatric Society, Centre for Perioperative Care. Guideline for the care of people living with frailty undergoing elective and emergency surgery that encompasses the whole perioperative pathway. Sep 2021 [internet publication].Full text
253. NHS England. Toolkit for general practice in supporting older people living with frailty. March 2017 [internet publication]Full text
254. British Geriatrics Society (BGS), Getting It Right First Time (GIRFT). Six steps to better care for older people in acute hospitals. Jul 2023 [internet publication].Full text
255. Rockwood K; British Geriatrics Society. Silver book II: frailty. February 2021 [internet publication]Full text
256. Falk Erhag H, Guðnadóttir G, Alfredsson J, et al. The association between the clinical frailty scale and adverse health outcomes in older adults in acute clinical settings: a systematic review of the literature. Clin Interv Aging. 2023 Feb;18:249-61.Full text Abstract
257. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024 Apr;105(4s):S117-S314.Full text Abstract
258. Conroy SP, Bardsley M, Smith P, et al. Comprehensive geriatric assessment for frail older people in acute hospitals: the HoW-CGA mixed-methods study. Health Services and Delivery Research. 2019 April:7(15)Full text
259. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13 Abstract
260. Fritz Z, Slowther AM, Perkins GD. Resuscitation policy should focus on the patient, not the decision. BMJ. 2017 Feb 28;356:j813Full text Abstract
261. British Medical Association, the Resuscitation Council (UK) and the Royal College of Nursing. Decisions relating to cardiopulmonary resuscitation. 2016 [internet publication].Full text
262. The National Institute for Health and Care Excellence. Decision making and mental capacity. October 2018 [internet publication]Full text
263. Office of the Public Guardian. Mental Capacity Act: making decisions. Jun 2023 [internet publication]Full text
264. Social Care Institute for Excellence. Independent mental capacity advocate (IMCA). January 2010 [internet publication]Full text
265. Joint British Diabetes Societies for Inpatient Care. The management of diabetic ketoacidosis in adults. Mar 2023 [internet publication].Full text
266. Joint British Diabetes Societies for Inpatient Care. The management of the hyperosmolar hyperglycaemic state (HHS) in adults. Feb 2022 [internet publication].Full text
267. Chowdhury TA, Cheston H, Claydon A. Managing adults with diabetes in hospital during an acute illness. BMJ. 2017 Jun 22;357:j2551 Abstract
268. Joint British Diabetes Societies for Inpatient Care. Self-management of diabetes in hospital. Feb 2023 [internet publication].Full text
269. Joint British Diabetes Societies for Inpatient Care. Glycaemic management during enteral feeding for people with diabetes in hospital. Apr 2024 [internet publication].Full text
270. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. Oct 2014 [internet publication].Full text
271. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].Full text
272. Centre for Perioperative Care. Guideline for perioperative care for people with diabetes mellitus undergoing elective and emergency surgery. Dec 2022 [internet publication].Full text
273. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88Full text Abstract
274. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. March 2020 [internet publication]Full text
275. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Jun 15;38(9):1687-93 Abstract
276. Umapathysivam MM, Gunton J, Stranks SN, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024 Jan 1;47(1):140-3.Full text Abstract
277. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S295-306.Full text Abstract
278. Joint British Diabetes Societies for Inpatient Care. A good inpatient diabetes service. Jul 2019 [internet publication].Full text
279. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. Aug 2022 [internet publication].Full text
280. Joint British Diabetes Societies for Inpatient Care. Inpatient care of the frail older adult with diabetes. Feb 2023 [internet publication].Full text
281. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67Full text Abstract
282. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text Abstract
283. Marik PE, Preiser JC. Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis. Chest. 2010 Mar;137(3):544-51Full text Abstract
284. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8Full text
285. NHS Digital. National Diabetes Inpatient Audit (NaDIA) - 2019. Nov 2020 [internet publication]Full text
286. Joint British Diabetes Societies for Inpatient Care. The hospital management of hypoglycaemia in adults with diabetes mellitus. Jan 2023 [internet publication].Full text
287. TREND Diabetes. End of life guidance for diabetes care. November 2021 [internet publication]Full text
288. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication]Full text
289. Rayman G, Vas PR, Baker N, et al. The Ipswich Touch Test: a simple and novel method to identify inpatients with diabetes at risk of foot ulceration. Diabetes Care. 2011 May 18;34(7):1517-8Full text Abstract
290. National Institute for Health and Care Excellence. Acute kidney injury: prevention, detection and management. Oct 2024 [internet publication].Full text
291. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2024 [internet publication].Full text
292. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60Full text Abstract
293. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51Full text Abstract
294. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7Full text Abstract
295. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21Full text Abstract
296. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51Full text Abstract
297. Walters JA, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897Full text Abstract
298. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. July 2019 [internet publication]Full text
299. Mitchell C, Zuraw N, Delaney B, et al. Primary care for people with severe mental illness and comorbid obstructive airways disease: a qualitative study of patient perspectives with integrated stakeholder feedback. BMJ Open. 2022 Mar 1;12(3):e057143Full text Abstract
300. National Institute for Health and Care Research (NIHR). How to improve care for people with a severe mental illness and a lung condition [internet publication]Full text
301. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. July 2019 [internet publication].Full text
302. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 [internet publication]Full text
303. National Institute for Health and Care Excellence. Depression in adults: treatment and management. Jun 2022 [internet publication]Full text
304. Horowitz M, Taylor DM. The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs. Chichester: Wiley-Blackwell; 2024.
305. Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015 May 12;29(5):459-525Full text Abstract
306. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. Abstract
307. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626 Abstract
308. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97Full text Abstract
309. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40Full text Abstract
310. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid. 2016 Jun;11(6)4-7Full text
311. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94
312. Oliveira P, Ribeiro J, Donato H, Madeira N. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017;16:17Full text Abstract
313. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. Feb 2025 [internet publication].Full text
314. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;6(6):CD013308Full text Abstract
315. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77.Full text Abstract
316. Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax. 2024 Mar 26;79(suppl 1):3-11.Full text Abstract
317. Lindson N, Theodoulou A, Ordóñez-Mena JM, et al. Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses. Cochrane Database Syst Rev. 2023 Sep 12;9(9):CD015226.Full text Abstract
318. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.Full text Abstract
319. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 June 28;6(6):CD006103Full text
Use of this content is subject to our disclaimer